Chlorprothixene - instructions for use, doses, side effects, contraindications, price, where to buy

Chlorprothixen

When using any antipsychotic, there is a risk of developing neuroleptic malignant syndrome (hyperthermia, muscle rigidity, fluctuations in consciousness, instability of the autonomic nervous system).

Patients with pre-existing psychoorganic syndrome, mental retardation, as well as those who abuse opiates and alcohol make up a significant proportion of deaths.

Treatment: discontinuation of the antipsychotic. Symptomatic therapy and general supportive treatment measures. Dantrolene and bromocriptine may be effective. After taking antipsychotics by mouth, symptoms may persist for more than one week.

Acute attacks of glaucoma due to pupil dilation can occur in patients with the rare shallow anterior chamber syndrome and in patients with a narrow anterior chamber angle.

Due to the risk of malignant arrhythmias, Chlorprothixene should be used with caution in patients with a history of cardiovascular disease and in patients with a family history of long QT interval (see section "Caution").

Before starting treatment, an ECG examination should be performed.

The use of the drug Chlorprothixene is contraindicated if the QTc interval at the initial measurement exceeds 450 ms in men and 470 ms in women (see section "Contraindications"). During treatment, the need for ECG monitoring should be assessed on an individual basis. During the treatment period, the dose should be reduced if the QT interval increases, and therapy should be discontinued if the QTc interval is >500 ms.

It is recommended to periodically monitor water and electrolyte balance indicators.

The simultaneous use of other antipsychotic drugs should be avoided (see section "Interaction with other drugs").

Like other antipsychotics, Chlorprothixene should be used with caution in patients with psychoorganic syndrome, seizures, liver, kidney and cardiovascular diseases in the later stages, as well as patients with myasthenia gravis and benign prostatic hyperplasia.

Caution must be exercised when using the drug in patients with:

pheochromocytoma,
prolactin-dependent tumors,
severe arterial hypotension or orthostatic dysregulation,
Parkinson's disease,
diseases of the hematopoietic system,
hyperthyroidism,
urinary disorders, urinary retention,
pyloric stenosis (pyloric stenosis), intestinal obstruction (see section “With caution”).

Like other psychotropic drugs, Chlorprothixene may affect blood glucose levels in patients with diabetes mellitus, which may require dose adjustment of antidiabetic drugs (insulin or oral hypoglycemic drugs).

Patients undergoing long-term treatment, especially with high doses, are subject to careful monitoring over time with periodic assessment of the need to reduce the maintenance dose.

Cases of venous thromboembolism (VTE) have been reported while taking antipsychotic drugs. Due to the fact that patients treated with antipsychotic drugs are often at risk for developing VTE, risk factors for VTE should be identified before and during treatment with chlorprothixene and precautions taken.

It has been reported that antipsychotics with α-adrenergic blocking effects may cause priapism; it is possible that chlorprothixene also has this property. If severe priapism occurs, medical intervention may be required. Patients should be warned about the need to urgently seek medical help if objective and subjective signs of priapism appear.

Use of the drug in children and adolescents under 18 years of age

Chlorprothixene is not recommended for use in children and adolescents. A sufficient number of clinical studies aimed at studying the effectiveness and safety of the use of chlorprothixene for the treatment of children and adolescents have not been conducted.

Elderly patients

Cerebrovascular adverse reactions

According to randomized placebo-controlled trials in populations of patients with dementia, the use of some atypical antipsychotics was associated with an approximately 3-fold increase in the risk of cerebrovascular adverse reactions. The mechanism by which this risk increases is unknown. A similar increase in risk cannot be excluded for other antipsychotics and other patient groups. In patients with risk factors for stroke, Chlorprothixene should be used with caution (see section "With caution").

Elderly patients are especially at risk of developing orthostatic hypotension.

Increased mortality in older patients with dementia

Data from two large observational studies showed that older patients with dementia taking antipsychotic drugs had a nonsignificant increased risk of death compared with patients not taking antipsychotic drugs. There is no sufficient data to accurately assess the magnitude of the risk and the reasons for its increase.

Chlorprothixene is not registered for the treatment of behavioral disorders in elderly patients with dementia.

To avoid the development of withdrawal syndrome, it is necessary to stop treatment with Chlorprothixene gradually.

Excipients

Chlorprothixene tablets contain lactose monohydrate. Patients with rare hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take this drug.

Chlorprothixene 15 mg 30 pcs. film-coated tablets

pharmachologic effect

Antipsychotic (neuroleptic).

Composition and release form Chlorprothixene 15 mg 30 pcs. film-coated tablets

Tablets - 1 tablet:

Active ingredient: chlorprothixene hydrochloride - 15.00 mg;
Excipients: lactose monohydrate (milk sugar) - 56.28 mg; microcrystalline cellulose - 9.90 mg; corn starch - 9.90 mg; copovidone - 4.95 mg; croscarmellose sodium - 1.98 mg; magnesium stearate - 0.99 mg;
Shell composition: hypromellose - 1.32 mg; macrogol-4000 - 0.36 mg; titanium dioxide - 0.72 mg.

10, 25, 30 or 50 tablets in a blister pack made of polyvinyl chloride film and printed varnished aluminum foil.

10, 25, 30, 50 or 100 tablets in jars made of polyethylene terephthalate for medicines or polypropylene for medicines, sealed with high-density polyethylene caps with first opening control, or polypropylene caps with a “push-turn” system, or polyethylene caps low pressure with first opening control.

One can or 1, 2, 3, 4, 5 or 10 blister packs along with instructions for use are placed in a cardboard package (pack).

Description of the dosage form

Round, biconvex tablets, film-coated, white or almost white. A cross-section of the tablets shows: the core is almost white or with a yellowish tint.

Directions for use and doses

The tablets are swallowed whole with water.

The dosage is selected individually depending on the patient's condition. Typically, small doses are prescribed at the beginning of treatment and increased to the optimal effective level as quickly as possible, depending on the therapeutic response.

Schizophrenia and other psychoses. Manic states

Treatment begins with 50-100 mg per day, gradually increasing the dose until the optimal effect is achieved, usually up to 300 mg per day. In some cases, the dose can be increased to 1200 mg per day.

The maintenance dose is usually 100-200 mg per day.

The daily dose of chlorprothixene is usually divided into 2-3 doses.

Given the sedative effect of chlorprothixene, it is recommended to prescribe a smaller part of the daily dose in the daytime, and the larger part in the evening.

Withdrawal syndrome in alcoholism and drug addiction

The daily dose, divided into 2-3 doses, is 500 mg for a period of up to 7 days. After symptoms of withdrawal disappear, the dose is gradually reduced.

A maintenance dose of 25-75 mg per day allows you to stabilize the condition and reduces the risk of developing another binge. Further dose reduction may be required.

Depressive states, neuroses, psychosomatic disorders

Chlorprothixene can be used for depression, especially when combined with anxiety, tension, as an addition to antidepressant therapy or independently.

Chlorprothixene can be prescribed for neuroses and psychosomatic disorders accompanied by anxiety and depressive disorders at a dose of up to 75 mg per day.

The daily dose is usually 2-3 doses. Since taking chlorprothixene does not cause addiction or drug dependence, it can be used for a long time. The maximum dose is 150 mg per day.

Epilepsy and mental retardation combined with mental disorders

The daily dose is 50 mg and is usually divided into 2-3 doses. The daily dose can be increased to 75-100 mg per day. For epilepsy, an adequate dose of anticonvulsant should be maintained.

Elderly patients

In elderly patients, the dose is selected individually. The dose range is 25-75 mg per day.

Insomnia

25 mg 1 hour before bedtime once.

Pain

The ability of chlorprothixene to potentiate the action of analgesics can be used in the treatment of patients with pain. In these cases, chlorprothixene is prescribed in doses of 75 to 300 mg per day; it can be used in conjunction with analgesics.

Children and adolescents (under 18 years of age)

Chlorprothixene is not recommended for use in children and adolescents under 18 years of age due to insufficient data on the safety and effectiveness of the drug in this age group.

Patients with impaired renal function

In patients with impaired renal function, the dosage should be selected with caution, and, if possible, the concentration of the drug in the blood plasma should be monitored.

Patients with liver dysfunction

In patients with impaired liver function, the dosage should be selected with caution, and, if possible, the concentration of the drug in the blood plasma should be monitored.

Pharmacodynamics

Chlorprothixene is an antipsychotic drug derived from thioxanthene. It has antipsychotic, pronounced sedative and moderate antidepressant effects.

Pharmacodynamics

The antipsychotic effect of neuroleptics is associated with blockade of dopamine receptors, and also, possibly, blockade of 5-HT (5-hydroxytryptamine) receptors.

In vivo, chlorprothixene has a high affinity for dopamine receptors type D1 and D2. Chlorprothixene also has high affinity for 5-HT2 receptors, α1-adrenergic receptors, histamine (H1) and cholinergic muscarinic receptors.

The receptor binding profile of chlorprothixene is very similar to that of clozapine, but it has approximately 10 times higher affinity for dopamine receptors.

Chlorprothixene reduces the severity or eliminates anxiety, obsessions, psychomotor agitation, restlessness, insomnia, as well as hallucinations, delusions and other psychotic symptoms.

The very low incidence of extrapyramidal effects (about 1%) and tardive dyskinesia (about 0.05%) indicate that chlorprothixene can be successfully used for maintenance treatment of patients with psychotic disorders.

Low doses of chlorprothixene have an antidepressant effect, which makes the drug useful for mental disorders characterized by anxiety, depression and restlessness.

Also, during therapy with chlorprothixene, the severity of associated psychosomatic symptoms decreases.

Chlorprothixene does not cause addiction, dependence or tolerance.

In addition, chlorprothixene potentiates the effect of analgesics, has its own analgesic effect, as well as antipruritic and antiemetic effects.

Pharmacokinetics

Suction

When taken orally, the maximum plasma concentration (Cmax) is achieved in approximately 2 hours (range 0.5-6 hours). The average oral bioavailability of chloprothixene is approximately 12% (range 5-32%).

Distribution

The apparent volume of distribution (Vdβ) is approximately 15.5 l/kg. Plasma protein binding is more than 99%.

Chlorprothixene penetrates the placental barrier.

Biotransformation

The metabolism of chlorprothixene occurs primarily through sulfoxidation and N-demethylation of the side chain. Ring hydroxylation and N-oxidation are less pronounced. Chlorprothixene is determined in bile, which indicates the presence of enterohepatic circulation of the drug. Metabolites of chlorprothixene lack neuroleptic activity.

Removal

The half-life (T1/2) is approximately 16 hours (range 4-33 hours). The average systemic clearance (Cls) corresponds to approximately 1.2 l/min. Excretion of chlorprothixene occurs through the intestines and kidneys.

In women who are breastfeeding, chlorprothixene is excreted in milk in small quantities. The ratio of drug concentrations in breast milk and blood plasma varies from 1.2 to 2.6.

There were no differences in plasma concentrations or elimination rates between the control group and the alcoholic group, regardless of whether the latter were sober or acutely intoxicated at the time of the study.

Indications for use Chlorprothixene 15 mg 30 pcs. film-coated tablets

Schizophrenia and other psychoses occurring with psychomotor agitation, agitation and anxiety.

Withdrawal syndrome in alcoholism and drug addiction.

Depressive states, neuroses, psychosomatic disorders with anxiety, tension, restlessness, insomnia, sleep disorders.

Epilepsy and mental retardation, combined with mental disorders: agitation, agitation, mood lability and behavioral disorders.

Pain (in combination with analgesics).

Geriatrics: hyperactivity, agitation, irritability, confusion, anxiety, behavioral and sleep disorders.

Contraindications

Hypersensitivity to chlorprothixene or any of the excipients.

Hypersensitivity to drugs of the thioxanthene group.

Vascular collapse, depression of consciousness of any origin (including those caused by alcohol, barbiturates or opiates), coma.

Established uncorrectable hypokalemia or hypomagnesemia.

Patients have a history of clinically significant cardiovascular diseases (for example, bradycardia (heart rate less than 50 beats per minute), recent myocardial infarction, decompensated heart failure, cardiac hypertrophy, arrhythmias for which class IA and III antiarrhythmics are prescribed), ventricular arrhythmias or polymorphic ventricular tachycardia of the “pirouette” type (Torsade de Pointes). Congenital long QT syndrome or acquired long QT interval (QTc over 450 ms in men and 470 ms in women).

Concomitant use with drugs that significantly prolong the QT interval.

Lactose intolerance, lactose deficiency or glucose-galactose malabsorption.

With caution: organic brain diseases; mental retardation; a family history of relatives suffering from cardiovascular diseases, as well as cases of prolongation of the QT interval; seizure disorders; severe liver and kidney failure; a rare pathological condition in the form of a small anterior chamber of the eye and its narrow angle (possible development of attacks of acute glaucoma associated with pupil dilation); myasthenia gravis; benign prostatic hypertrophy; pheochromocytoma; prolactin-dependent neoplasms; severe arterial hypotension or orthostatic disorders; Parkinson's disease; diseases of the hematopoietic system; hyperthyroidism; painful urination, urinary retention; pyloric stenosis; intestinal obstruction, presence of risk factors for stroke; diabetes; abuse of opiates and alcohol; pregnancy, breastfeeding period; age under 18 years (due to insufficient controlled clinical studies).

Application Chlorprothixene 15 mg 30 pcs. film-coated tablets during pregnancy and breastfeeding

Pregnancy

Clinical experience with the use of chlorprothixene in pregnant women is limited. Chlorprothixene should not be used during pregnancy unless the potential benefit to the patient outweighs the possible risk to the fetus. Neonates exposed to antipsychotics (including chlorprothixene) during the third trimester of pregnancy are at risk of developing adverse reactions, including extrapyramidal symptoms and/or side effect syndrome. These adverse reactions may have a negative impact on sexual function and fertility in women and/or men.

If clinically significant hyperprolactinemia, galactorrhea, amenorrhea or manifestations of sexual dysfunction occur, dosage reduction (if possible) or discontinuation of the drug should be considered. These side effects are reversible after discontinuation of the drug.

The potential effects of the drug on fertility have not been studied in animals.

special instructions

When using any antipsychotic, there is a risk of developing neuroleptic malignant syndrome (hyperthermia, muscle rigidity, fluctuations in consciousness, instability of the autonomic nervous system).

Patients with pre-existing psychoorganic syndrome, mental retardation, as well as those who abuse opiates and alcohol make up a significant proportion of deaths.

Acute attacks of glaucoma due to pupil dilation can occur in patients with the rare shallow anterior chamber syndrome and in patients with a narrow anterior chamber angle.

Due to the risk of malignant arrhythmias, Chlorprothixene should be used with caution in patients with a history of cardiovascular disease and in patients with a family history of long QT interval.

Before starting treatment, an ECG examination should be performed.

It is recommended to periodically monitor water and electrolyte balance indicators.

Concomitant use of other antipsychotic drugs should be avoided.

Caution must be exercised when using the drug in patients with:

pheochromocytoma;
prolactin-dependent tumors;
severe arterial hypotension or orthostatic dysregulation;
Parkinson's disease;
diseases of the hematopoietic system;
hyperthyroidism;
urinary disorders, urinary retention;
pyloric stenosis (pyloric stenosis), intestinal obstruction.

Patients undergoing long-term treatment, especially with high doses, are subject to careful monitoring over time with periodic assessment of the need to reduce the maintenance dose.

Use of the drug in children and adolescents under 18 years of age

Elderly patients

Cerebrovascular adverse reactions

Elderly patients are especially at risk of developing orthostatic hypotension.

Increased mortality in older patients with dementia

Chlorprothixene is not registered for the treatment of behavioral disorders in elderly patients with dementia.

To avoid the development of the syndrome "pirouette" ventricular tachycardia (Torsade de Pointes), cardiac arrest and ventricular arrhythmias were observed with simultaneous overdose with drugs that affect cardiac activity.

Treatment: symptomatic and supportive. Gastric lavage should be performed as soon as possible after administration; the use of activated charcoal is recommended. Measures should be taken to maintain the functioning of the respiratory and cardiovascular systems. Epinephrine should not be used as this may lead to a subsequent decrease in blood pressure.

Seizures can be treated with diazepam, and extrapyramidal disorders with biperiden.

A dose of 2.5 to 4 g can be lethal (in children approximately 4 mg/kg). Some adults survived after taking 10 g, and a 3-year-old child survived after taking 1000 mg.

Side effects Chlorprothixene 15 mg 30 pcs. film-coated tablets

The most common adverse reactions, which may occur in more than 10% of patients, are dry mouth, increased salivation, drowsiness and dizziness.

Most side effects depend on the dose of the drug used. The incidence of side effects and their severity are most pronounced at the beginning of treatment and decrease as therapy continues.

Information on the incidence of side effects is presented based on literature data and spontaneous reports.

The frequency of adverse reactions listed below was determined according to the World Health Organization classification: very often - more than 1/10, often - from more than 1/100 to less than 1/10, infrequently - from more than 1/1000 to less than 1/100, rarely - from more than 1/10000 to less than 1/1000, very rarely - from less than 1/10000 (including individual reports), frequency unknown - based on available data, it is not possible to determine the frequency of occurrence of an adverse reaction.

Disorders of the blood and lymphatic system: rarely - thrombocytopenia, neutropenia, leukopenia, agranulocytosis.

Immune system disorders: rarely - hypersensitivity, anaphylactic reactions.

Endocrine system disorders: rarely - hyperprolactinemia.

Metabolic and nutritional disorders: often - increased appetite, weight gain; infrequently - loss of appetite, loss of body weight; rarely - hyperglycemia, impaired glucose tolerance.

Mental disorders: often - insomnia, nervousness, agitation, decreased libido.

Nervous system disorders: very often - drowsiness, dizziness; often - dystonia, headache; uncommon - tardive dyskinesia, parkinsonism, seizures, akathisia; very rarely - neuroleptic malignant syndrome.

Violations of the organ of vision: often - disturbance of accommodation, blurred vision; infrequently - movement of the eyeballs.

Cardiac disorders: often - tachycardia, palpitations; rarely - prolongation of the QT interval on the electrocardiogram (ECG).

Vascular disorders: infrequently - arterial hypotension, “flushes” of blood to the skin of the face with a feeling of heat; very rarely - venous thromboembolism.

Disorders of the respiratory system, chest and mediastinal organs: rarely - shortness of breath.

Gastrointestinal disorders: very often - dry mouth, increased salivation; often - constipation, dyspepsia, nausea; infrequently - vomiting, diarrhea.

Disorders of the liver and biliary tract: infrequently - changes in laboratory parameters of liver function; very rarely - jaundice.

Disorders of the skin and subcutaneous tissues: often - increased sweating; uncommon - skin rash, itching, photosensitivity, dermatitis.

Musculoskeletal and connective tissue disorders: often - myalgia; infrequently - muscle rigidity.

Renal and urinary tract disorders: uncommon - urinary retention, painful urination.

Pregnancy, postpartum and perinatal conditions: frequency unknown - neonatal syndrome "Torsade de Pointes".

During the use of antipsychotic drugs, cases of priapism have been recorded - prolonged erection, usually painful, which can lead to erectile dysfunction. The frequency of this phenomenon is unknown.

Withdrawal syndrome. The most common symptoms are nausea, vomiting, anorexia, diarrhea, rhinorrhea, sweating, myalgia, paresthesia, insomnia, nervousness, anxiety and agitation. Patients may also experience dizziness, alternating sensations of heat and cold, and tremors of the limbs. Symptoms usually begin within 1-4 days after discontinuation and decrease within 7-14 days.

Drug interactions

Chlorprothixene may enhance the sedative effect of ethanol and the effects of barbiturates and other CNS depressants.

Chlorprothixene should not be prescribed together with guanethidine and similar acting drugs, since antipsychotics can increase or decrease the effect of antihypertensive drugs, the antihypertensive effect of guanethidine and similar acting drugs is reduced.

Concomitant use of antipsychotics and lithium drugs increases the risk of neurotoxicity.

Tricyclic antidepressants and antipsychotics mutually inhibit each other's metabolism.

Chlorprothixene may reduce the effectiveness of levodopa and adrenergic drugs.

The simultaneous use of chlorprothixene and drugs with established anticholinergic effects enhances their anticholinergic effects.

With the simultaneous use of metoclopramide and piperazine, the risk of developing extrapyramidal symptoms increases.

The antihistamine effect of chlorprothixene may reduce or eliminate the symptoms of the disulfiram-ethanol reaction.

Prolongation of the QT interval on the ECG associated with treatment with antipsychotics may be exacerbated by concomitant use of other drugs that significantly prolong the QT interval.

The simultaneous use of chlorprothixene is contraindicated with the following drugs:

class IA and class III antiarrhythmics (eg, quinidine, amiodarone, sotalol, dofetilide);
some antipsychotic drugs (eg, thioridazine);
some antibiotics from the macrolide group (for example, erythromycin);
some antihistamines (for example, terfenadine, astemizole);
some antibiotics from the quinolone group (for example, gatifloxacin, moxifloxacin);
cisapride and lithium preparations.

The simultaneous use of chlorprothixene and the above drugs should be avoided.

Chlorprothixene should also be used with caution concurrently with drugs that cause electrolyte disturbances (thiazide and thiazide-like diuretics) and drugs that can increase plasma concentrations of chlorprothixene due to a possible increased risk of QT prolongation and life-threatening arrhythmias.

Neuroleptics are metabolized by isoenzymes of the cytochrome P450 system in the liver. Drugs that inhibit the CYP2D6 isoenzyme (for example, paroxetine, fluoxetine, chloramphenicol, disulfiram, isoniazid, monoamine oxidase inhibitors (MAOIs), oral contraceptives, and to a lesser extent buspirone, sertraline or citalopram) may increase the plasma concentration of chlorprothixene.

Chlorprothixene and alcohol consequences. "Chlorprothixene": reviews. Instructions, pros and cons of the drug

Tablets "Chlorprothixene" (or "Chlorprothixene Zentiva") are a drug that has anticonvulsant, antipsychotic, neuroleptic, and analgesic effects. It can be prescribed by doctors for a whole range of problems, ranging from depression to brain injury. This article contains detailed information about the drug “Chlorprothixene”: why and in what quantity it is prescribed, what contraindications it has, what side effects it causes. You will also find out how doctors and patients themselves speak about it.

Indications for use

The medicine "Chlorprothixene", instructions for which are always included in the package, can be prescribed for the following health problems:

— Behavioral disorders in children.

— Psychoses, including schizophrenia and manic syndrome, accompanied by fear, aggression, and anxiety.

- Neuroses, depression.

- Confusion, agitation in older people.

- For hangover syndrome, alcoholism and drug addiction.

- For brain injuries.

— For pain of various etiologies as a drug that enhances the effect of analgesics.

- During acclimatization.

— Postoperative and post-burn conditions.

- For convulsive cough.

- If there are spasms in the gastrointestinal tract.

Release form and composition

The drug "Chlorprothixene Zentiva" is sold in the form of tablets of 15 or 50 mg. The active substance of the drug is chlorprothixene hydrochloride. Auxiliary elements are: corn starch, lactose monohydrate, calcium stearate, sucrose, talc.

How to use?

— For psychoses and schizophrenia, therapy begins with 50–100 mg per day, gradually increasing the dose until a positive result is obtained. Usually limited to 300 mg of the drug per day. In some cases, the dose may be increased to 1200 mg. The daily dose of medication is divided into 2 or 3 approaches. The maintenance dose of the drug is usually 100–200 mg per day.

— The medication “Chlorprothixene”, the dosage of which is individual depending on the disease, is prescribed for hangover syndrome, as well as for alcoholism and drug addiction in the following amount: 500 mg per day. Moreover, one-time use of tablets is prohibited; they must be taken 2 or 3 times a day. Treatment usually lasts 1 week. After the condition improves, the dose is gradually reduced to 15–45 mg per day, which reduces the risk of another binge.

— For irritability, agitation, and confusion in elderly patients, they are prescribed from 15 to 90 mg of the drug per day.

— For children, to correct their negative behavioral reactions, the doctor may prescribe the medicine “Chlorprothixene” from 0.5 to 2 mg per 1 kg of body weight. That is, if a boy or girl weighs, for example, 20 kg, then the doctor prescribes 10-40 mg of the drug per day.

— For depression, neuroses, and psychosomatic disorders, the doctor often prescribes up to 90 mg of medication per day. And as usual, the daily dose is divided into several doses. The drug "Chlorprothixene", the indications for use of which state that the drug copes well with prostration, blues and despondency, cannot be used for a long time, since the tablets are addictive.

— For insomnia, 15–30 mg of medication is prescribed in the evening, 1 hour before bedtime.

The main dosage regimens for Chlorprothixene were reviewed. The use of the drug must be agreed with the doctor. And only a specialist, after conducting an examination, can prescribe the correct dosage of the medicine. Doctors also emphasize that you should stop taking pills gradually. Rapid withdrawal may result in undesirable symptoms such as vomiting, headache, insomnia, increased sweating, and anxiety. The tablets should be taken during or after meals and should be swallowed whole. You cannot bite them or make powder out of them.

Pharmacological properties of the drug Chlorprothixene

Chlorprothixene is an antipsychotic, a thioxanthene derivative. It also has sedative, antiemetic, antidepressant and antihistamine effects. The antipsychotic effect is due to the blockade of dopamine D2 receptors in the mesolimbic and mesocortical systems. It has antiserotonin, cholinergic and adrenergic blocking activity. The sedative effect is due to the blockade of adrenergic receptors in the reticular formation of the brain stem; antiemetic effect - blockade of dopamine D2 receptors in the trigger zone of the vomiting center; hypothermic effect - blockade of dopamine receptors of the hypothalamus; antihistamine - blockade of H1 receptors. Quickly absorbed from the digestive tract; After oral administration, the effect occurs within 20 minutes. It undergoes first-pass metabolism in the intestinal walls and liver. Has a first pass effect through the liver. Penetrates through the placental barrier and into breast milk. Metabolized in the body. It is excreted in urine and feces, primarily in the form of metabolites (at a daily dose of 300 mg - about 29% as chlorprothixene, 41% as chlorprothixene sulfoxide). The half-life is 8–12 hours.